Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking
Abstract The application of monoclonal antibodies as targeted drugs has revolutionized cancer therapy, yet their efficacy is sometimes limited by toxicities arising from target expression in healthy tissues. Various strategies have emerged to overcome these issues, including the design of antibody-b...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2026-06-01
|
| Rangatū: | Journal of Biological Engineering |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s13036-026-00705-1 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|